Neuronetics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STIM research report →
Range $5 – $5
Price Chart
About the company
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U. S.
- CEO
- Daniel L. Reuvers
- IPO
- 2018
- Employees
- 658
- HQ
- Malvern, PA, US
Get TickerSpark's AI analysis on STIM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $97.16M
- P/E
- -3.88
- PEG
- -0.04
- P/S
- 0.61
- P/B
- 5.15
- EV/EBITDA
- -13.50
- Div Yield
- 0.00%
- Gross Margin
- 50.68%
- Op Margin
- -9.39%
- Net Margin
- -14.45%
- ROE
- -127.86%
- ROIC
- -13.62%
Latest fiscal year · YoY change
- Revenue
- $149.16M+99.2%
- Gross Profit
- $72.31M+33.5%
- Op Income
- $-31,436,000
- Net Income
- $-38,998,000+10.8%
- EPS
- $-0.59+57.2%
- OCF Growth
- +34.3%
- FCF Growth
- +34.8%
- 52W High
- $3.44
- 52W Low
- $0.80
- 50D MA
- $2.18
- 200D MA
- $1.86
- Beta
- 1.20
- RSI (14)
- 30
- Avg Volume
- 1.76M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Neuronetics posted a strong Q3 with double-digit revenue growth, improved margins, and positive EBITDA/cash flow, while management leaned into a new go-to-market strategy and clinic efficiency gains.· November 4, 2026
- Total revenue rose to approximately $42 million, up 12.5% year over year, with gross margin expanding to 52.2% from 45.9%.
- Greenbrook revenue increased 20.1% to $26.2 million, helped by better revenue cycle management and growing Spravato activity.
- NeuroStar revenue was $15.8 million, up 1.8%, driven by a record quarter of system sales; more than half of units sold were capital or lease.
- Operating expenses fell 12.6% to $21.3 million, and the company reported positive operating income of $5 million and adjusted EBITDA of $1.9 million.
- Management kept full-year 2026 guidance mostly intact, with total revenue still targeted at $160 million to $164 million and gross margin now expected at 49% to 50%.
Total revenue was approximately $42 million, up 12.5% from $37.3 million a year ago. Greenbrook revenue was $26.2 million, up 20.1%; NeuroStar revenue was $15.8 million, up 1.8%. Gross margin was 52.2% versus 45.9% last year. Operating expenses were $21.3 million, down 12.6% from $24.4 million. Income from operations was $5 million versus a loss of $7.3 million, net loss attributable to stockholders was $1.7 million, or $0.02 per share, versus $9 million, or $0.13 per share, and adjusted EBITDA was $1.9 million versus a loss of $4.7 million. Cash at September 30 was $27.9 million, including $22.9 million of cash and cash equivalents and $5.8 million of restricted cash. Full-year 2026 guidance calls for total revenue of $160 million to $164 million, gross margin of 49% to 50%, operating expenses excluding stock-based compensation of $89 million to $92 million, operating expenses of $92.5 million to $95.5 million, and cash flow from operating and investing of negative $10 million to negative $12 million.
Daniel Reuvers said the company made meaningful progress on profitability and operating cash goals, and emphasized that Q3 reflected both a record NeuroStar system-sales quarter and continued strength in Greenbrook. He highlighted the expanded go-to-market strategy for NeuroStar, the move toward larger and more enterprise-type customers, and the company’s belief that these changes should support higher overall net growth in 2027 and beyond. On Greenbrook, he said the focus is on running clinics more efficiently, improving patient acquisition economics, and shifting resources toward field sales where returns appear better than direct-to-consumer advertising.
Nir Naor said the quarter showed solid financial progress: revenue grew to $42 million, gross margin improved to 52.2%, operating expenses declined to $21.3 million, and adjusted EBITDA turned positive at $1.9 million. He attributed margin improvement mainly to the new go-to-market strategy and improved revenue cycle management in Greenbrook, and said cash provided by operating and investing activities was $800 thousand versus negative $900 thousand last year. He also reiterated full-year guidance, including revenue of $160 million to $164 million and operating cash flow/ investing cash flow of negative $10 million to negative $12 million, while saying the company continues to target limited to no net cash utilization in the second half of the year.
Analysts focused on Greenbrook’s growth drivers, the durability of revenue cycle improvements, unused clinic capacity, and how much Spravato contributed. Management said Q3 growth came from a combination of revenue cycle management improvements and Spravato growth, and noted clinic occupancy still ranges widely, from as low as 25% at the bottom to 75% at the top. On the NeuroStar side, management said more than half of units sold were capital or lease, that the company is seeing growth from larger accounts, and that it is not expecting dramatic swings in gross margin from here. They also said the new EHR integration with AdvancedMD is an important first step and could support future integrations if the rollout proves valuable.
The bull case from this call is that the company is showing clear operating leverage: revenue is growing, gross margin expanded sharply, and both operating income and adjusted EBITDA turned positive. Management also sounded confident that Greenbrook’s revenue cycle and workflow changes are durable and that the NeuroStar go-to-market shift is opening up customers and account types they could not reach before.
The main risks flagged were that some benefits at Greenbrook will get harder to repeat as easier gains are captured, and management said future improvements will likely be more modest. They also noted that session revenue should keep trending slightly down as the mix shifts toward capital, that occupancy at some clinics remains low, and that the field-sales expansion is only expected to become meaningful by mid-2027. In addition, several initiatives are still early, including the FDA review for the accelerated TMS protocol, the AdvancedMD integration rollout, and the Compass-related commercial work.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 37.9%
- Shares Outstanding
- 77.73M
- Float Shares
- 29.46M
of shares held by institutions
92 13F filers
Buy/sell ratio 1.60. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Madryn Asset Management, LP | 18.54M | 0 |
| Vanguard Group Inc | 2.58M | ▼ 249.74K |
| Wexford Capital LP | 2.00M | 0 |
| Fourworld Capital Management LLC | 1.74M | ▲ 254.82K |
| Marshall Wace, Llp | 1.55M | ▲ 1.07M |
| Vanguard Capital Management LLC | 1.53M | ▲ 20.28K |
| Lane Generational LLC | 1.26M | ▼ 371.19K |
| Hightower Advisors, LLC | 1.10M | ▲ 537.76K |
| Masters Capital Management LLC | 1.00M | 0 |
| Advisorshares Investments LLC | 924.38K | ▲ 181.59K |
| Morgan Stanley | 753.32K | ▲ 690.43K |
| Ikarian Capital, LLC | 701.18K | 0 |
Held by 31 ETFs
Biggest fund positions in STIM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | MUIR GLENN P | other | 175,000 |
| Nov 16, 26 | MUIR GLENN P | other | 175,000 |
| Nov 12, 26 | CASCELLA ROBERT | other | 44,758 |
| Nov 12, 26 | CASCELLA ROBERT | other | 128,242 |
| Nov 13, 26 | Cucuz Sasha | other | 370,370 |
| Nov 12, 26 | Cucuz Sasha | other | 625,000 |
| Nov 6, 26 | Chernett Jorey | sell | 250,804 |
| Nov 9, 26 | Chernett Jorey | buy | 40,000 |
| Nov 9, 26 | Chernett Jorey | sell | 103,959 |
| Nov 11, 26 | Chernett Jorey | sell | 86,757 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our STIM coverage
Recent articles, reports, and earnings notes.
No research on STIM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STIM report →Here's Why Neuronetics (STIM) is Poised for a Turnaround After Losing 37.8% in 4 Weeks
zacks.com · Nov 19
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 18
Neuronetics (STIM) Loses 34.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com · Nov 17
Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
globenewswire.com · Nov 10
Neuronetics Announces Proposed Public Offering of Common Stock
globenewswire.com · Nov 10
Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 4
Neuronetics Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.